{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:18:55Z","timestamp":1785442735153,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00259-015-3184-5","type":"journal-article","created":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T20:36:51Z","timestamp":1444250211000},"page":"404-413","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Predictive value of 18F-FDG PET\/CT in restaging patients affected by ovarian carcinoma: a multicentre study"],"prefix":"10.1007","volume":"43","author":[{"name":"Young AIMN Working Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Caobelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Saladini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rensi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onelio","family":"Geatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Castello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iashar","family":"Laghai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina E.","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Dolci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Crivellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Seghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Kirienko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"De Biasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Cocciolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale","family":"Quartuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"3184_CR1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.20113","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183\u2013203.","journal-title":"CA Cancer J Clin"},{"key":"3184_CR2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374\u2013403.","journal-title":"Eur J Cancer"},{"key":"3184_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1\u20135.","journal-title":"Int J Gynaecol Obstet"},{"key":"3184_CR4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1258\/ar.2012.120632","volume":"54","author":"AA Zytoon","year":"2013","unstructured":"Zytoon AA, Murakami K, Eid H, El-Gammal M. High impact of FDG-PET\/CT in diagnostic strategies for ovarian cancer. Acta Radiol 2013;54:340\u20138.","journal-title":"Acta Radiol"},{"key":"3184_CR5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/IGC.0b013e31828a183c","volume":"23","author":"Z Limei","year":"2013","unstructured":"Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L. Accuracy of positron emission tomography\/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer 2013;23:598\u2013607.","journal-title":"Int J Gynecol Cancer"},{"key":"3184_CR6","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1097\/IGC.0000000000000180","volume":"24","author":"H Konishi","year":"2014","unstructured":"Konishi H, Takehara K, Kojima A, Okame S, Yamamoto Y, Shiroyama Y, et al. Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography\/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 2014;24:1190\u20134.","journal-title":"Int J Gynecol Cancer"},{"key":"3184_CR7","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/IGC.0b013e3182606ecb","volume":"22","author":"S Risum","year":"2012","unstructured":"Risum S, Loft A, Engelholm SA, H\u00f8gdall E, Berthelsen AK, Nedergaard L, et al. Positron emission tomography\/computed tomography predictors of overall survival in stage IIIC\/IV ovarian cancer. Int J Gynecol Cancer 2012;22:1163\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"3184_CR8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ygyno.2009.12.008","volume":"116","author":"S Risum","year":"2010","unstructured":"Risum S, H\u00f8gdall C, Loft A, Berthelsen AK, H\u00f8gdall E, Nedergaard L, et al. Does the use of diagnostic PET\/CT cause stage migration in patients with primary advanced ovarian cancer? Gynecol Oncol 2010;116:395\u20138.","journal-title":"Gynecol Oncol"},{"key":"3184_CR9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF03027426","volume":"20","author":"H Kurosaki","year":"2006","unstructured":"Kurosaki H, Oriuchi N, Okazaki A, Tamaki T, Uki A, Izuta M, et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann Nucl Med 2006;20:171\u20134.","journal-title":"Ann Nucl Med"},{"key":"3184_CR10","first-page":"53","volume":"66","author":"K Nakamura","year":"2012","unstructured":"Nakamura K, Hongo A, Kodama J, Hiramatsu Y. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer. Acta Med Okayama 2012;66:53\u201360.","journal-title":"Acta Med Okayama"},{"key":"3184_CR11","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1245\/s10434-011-2153-x","volume":"19","author":"HH Chung","year":"2012","unstructured":"Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 2012;19:1966\u201372.","journal-title":"Ann Surg Oncol"},{"key":"3184_CR12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1007\/s00259-014-2803-x","volume":"41","author":"JW Lee","year":"2014","unstructured":"Lee JW, Cho A, Lee JH, Yun M, Lee JD, Kim YT, et al. The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET\/CT in the prognosis of epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 2014;41:1898\u2013906.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3184_CR13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O\u2019Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181\u2013200.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3184_CR14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/RLU.0b013e31826390ec","volume":"38","author":"HW Kim","year":"2013","unstructured":"Kim HW, Won KS, Zeon SK, Ahn BC, Gayed IW. Peritoneal carcinomatosis in patients with ovarian cancer: enhanced CT versus 18F-FDG PET\/CT. Clin Nucl Med 2013;38:93\u20137.","journal-title":"Clin Nucl Med"},{"key":"3184_CR15","doi-asserted-by":"crossref","unstructured":"Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 2009;50 Suppl 1:64S\u201373.","DOI":"10.2967\/jnumed.108.057257"},{"key":"3184_CR16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejrad.2013.12.006","volume":"83","author":"CB Hebel","year":"2014","unstructured":"Hebel CB, Behrendt FF, Heinzel A, Krohn T, Mottaghy FM, Bauerschlag DO, et al. Negative 18F-2-fluorodeoxyglucose PET\/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Eur J Radiol 2014;83:463\u20137.","journal-title":"Eur J Radiol"},{"key":"3184_CR17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2014.12.032","volume":"136","author":"CY Kim","year":"2015","unstructured":"Kim CY, Jeong SY, Chong GO, Son SH, Jung JH, Kim DH, et al. Quantitative metabolic parameters measured on F-18 FDG PET\/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol 2015;136:498\u2013504. doi: 10.1016\/j.ygyno.2014.12.032 .","journal-title":"Gynecol Oncol"},{"key":"3184_CR18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00259-007-0627-7","volume":"35","author":"Y Nishiyama","year":"2008","unstructured":"Nishiyama Y, Yamamoto Y, Kanenishi K, Ohno M, Hata T, Kushida Y, et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging 2008;35:287\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3184_CR19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/RLU.0b013e31829f57fa","volume":"38","author":"S Liao","year":"2013","unstructured":"Liao S, Lan X, Cao G, Yuan H, Zhang Y. Prognostic predictive value of total lesion glycolysis from 18F-FDG PET\/CT in post-surgical patients with epithelial ovarian cancer. Clin Nucl Med 2013;38:715\u201320.","journal-title":"Clin Nucl Med"},{"key":"3184_CR20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11523-014-0309-x","volume":"9","author":"MJ Boers-Sonderen","year":"2014","unstructured":"Boers-Sonderen MJ, de Geus-Oei LF, Desar IM, van der Graaf WT, Oyen WJ, Ottevanger PB, et al. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET\/CT. Target Oncol 2014;9:339\u201347.","journal-title":"Target Oncol"},{"key":"3184_CR21","first-page":"1051","volume":"44","author":"T Torizuka","year":"2003","unstructured":"Torizuka T, Kanno T, Futatsubashi M, Okada H, Yoshikawa E, Nakamura F, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med 2003;44:1051\u20136.","journal-title":"J Nucl Med"},{"key":"3184_CR22","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1148\/radiol.2482071379","volume":"248","author":"T Tsujikawa","year":"2008","unstructured":"Tsujikawa T, Yoshida Y, Mori T, Kuokawa T, Fujibayashi Y, Kotsuji F, et al. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17-beta-estradiol and 18F fluorodeoxyglucose PET\u2014initial experience. Radiology 2008;248:599\u2013605.","journal-title":"Radiology"},{"key":"3184_CR23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/RLU.0b013e318292ee9c","volume":"38","author":"H Tsuyoshi","year":"2013","unstructured":"Tsuyoshi H, Morishita F, Orisaka M, Okazawa H, Yoshida Y. 18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients. Clin Nucl Med 2013;38:560\u20133.","journal-title":"Clin Nucl Med"},{"key":"3184_CR24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/IGC.0b013e3181a3cc94","volume":"19","author":"S Risum","year":"2009","unstructured":"Risum S, H\u00f8gdall C, Markova E, Berthelsen AK, Loft A, Jensen F, et al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer 2009;19:600\u20134.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"3184_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10147-005-0489-6","volume":"10","author":"M Takekuma","year":"2005","unstructured":"Takekuma M, Maeda M, Ozawa T, Yasumi K, Torizuka T. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 2005;10(3):177\u201381.","journal-title":"Int J Clin Oncol"},{"key":"3184_CR26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MNM.0000000000000051","volume":"35","author":"YM Chen","year":"2014","unstructured":"Chen YM, Chen T, Zee CS, Shi YP, Wan LR, Tong LJ. Is there an impact of 18F-FDG PET\/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET\/CT center. Nucl Med Commun 2014;35:347\u201352.","journal-title":"Nucl Med Commun"},{"key":"3184_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ssu.2980100107","volume":"10","author":"CL Kosary","year":"1994","unstructured":"Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973\u201387 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994;10:31\u201346.","journal-title":"Semin Surg Oncol"},{"key":"3184_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/RLU.0b013e3182291e03","volume":"37","author":"D Karantanis","year":"2012","unstructured":"Karantanis D, Allen-Auerbach M, Czernin J. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med. 2012;37:49\u201353.","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1","key":"3184_CR29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1525-1438.2006.00471.x","volume":"16","author":"M Murakami","year":"2006","unstructured":"Murakami M, Miyamoto T, Iida T, Tsukada H, Watanabe M, Shida M, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16 Suppl 1:99\u2013107.","journal-title":"Int J Gynecol Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3184-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-015-3184-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-015-3184-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:06:28Z","timestamp":1558699588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-015-3184-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,18]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["3184"],"URL":"https:\/\/doi.org\/10.1007\/s00259-015-3184-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,18]]}}}